BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 35852795)

  • 21. TP53 wild-type/PPM1D mutant diffuse intrinsic pontine gliomas are sensitive to a MDM2 antagonist.
    Xu C; Liu H; Pirozzi CJ; Chen LH; Greer PK; Diplas BH; Zhang L; Waitkus MS; He Y; Yan H
    Acta Neuropathol Commun; 2021 Nov; 9(1):178. PubMed ID: 34732238
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characteristics of children ≤36 months of age with DIPG: A report from the international DIPG registry.
    Bartlett AL; Lane A; Chaney B; Escorza NY; Black K; Cochrane A; Minturn J; Bartels U; Warren K; Hansford J; Ziegler D; Diez B; Goldman S; Packer R; Kieran M; DeWire-Schottmiller M; Erker C; Monje-Deisseroth M; Wagner L; Koschmann C; Dorris K; Shih CS; Hassall T; Samson Y; Fisher P; Wang SS; Tsui K; Sevlever G; Zhu X; Dexheimer P; Asher A; Fuller C; Drissi R; Jones B; Leach J; Fouladi M
    Neuro Oncol; 2022 Dec; 24(12):2190-2199. PubMed ID: 35552452
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The transcription factor Olig2 is important for the biology of diffuse intrinsic pontine gliomas.
    Anderson JL; Muraleedharan R; Oatman N; Klotter A; Sengupta S; Waclaw RR; Wu J; Drissi R; Miles L; Raabe EH; Weirauch ML; Fouladi M; Chow LM; Hoffman L; DeWire M; Dasgupta B
    Neuro Oncol; 2017 Aug; 19(8):1068-1078. PubMed ID: 28339768
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differential Expression of Wilms' Tumor Protein in Diffuse Intrinsic Pontine Glioma.
    Lee S; Kambhampati M; Yadavilli S; Gordish-Dressman H; Santi M; Cruz CR; Packer RJ; Almira-Suarez MI; Hwang EI; Nazarian J
    J Neuropathol Exp Neurol; 2019 May; 78(5):380-388. PubMed ID: 30990879
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Correlation of multimodal
    Morana G; Tortora D; Bottoni G; Puntoni M; Piatelli G; Garibotto F; Barra S; Giannelli F; Cistaro A; Severino M; Verrico A; Milanaccio C; Massimino M; Garrè ML; Rossi A; Piccardo A
    Theranostics; 2020; 10(26):11881-11891. PubMed ID: 33204317
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinicopathology of diffuse intrinsic pontine glioma and its redefined genomic and epigenomic landscape.
    Panditharatna E; Yaeger K; Kilburn LB; Packer RJ; Nazarian J
    Cancer Genet; 2015; 208(7-8):367-73. PubMed ID: 26206682
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Progress in diffuse intrinsic pontine glioma: advocating for stereotactic biopsy in the standard of care.
    Williams JR; Young CC; Vitanza NA; McGrath M; Feroze AH; Browd SR; Hauptman JS
    Neurosurg Focus; 2020 Jan; 48(1):E4. PubMed ID: 31896081
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Potent anti-tumor efficacy of palbociclib in treatment-naïve H3.3K27M-mutant diffuse intrinsic pontine glioma.
    Sun Y; Sun Y; Yan K; Li Z; Xu C; Geng Y; Pan C; Chen X; Zhang L; Xi Q
    EBioMedicine; 2019 May; 43():171-179. PubMed ID: 31060906
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characterization of the immune microenvironment of diffuse intrinsic pontine glioma: implications for development of immunotherapy.
    Lieberman NAP; DeGolier K; Kovar HM; Davis A; Hoglund V; Stevens J; Winter C; Deutsch G; Furlan SN; Vitanza NA; Leary SES; Crane CA
    Neuro Oncol; 2019 Jan; 21(1):83-94. PubMed ID: 30169876
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A phase I/II study of ribociclib following radiation therapy in children with newly diagnosed diffuse intrinsic pontine glioma (DIPG).
    DeWire M; Fuller C; Hummel TR; Chow LML; Salloum R; de Blank P; Pater L; Lawson S; Zhu X; Dexheimer P; Carle AC; Kumar SS; Drissi R; Stevenson CB; Lane A; Breneman J; Witte D; Jones BV; Leach JL; Fouladi M
    J Neurooncol; 2020 Sep; 149(3):511-522. PubMed ID: 33034839
    [TBL] [Abstract][Full Text] [Related]  

  • 31. TSPO PET Imaging as a Potent Non-Invasive Biomarker for Diffuse Intrinsic Pontine Glioma in a Patient-Derived Orthotopic Rat Model.
    Chevaleyre C; Kereselidze D; Caillé F; Tournier N; Olaciregui NG; Winkeler A; Declèves X; Jego B; Cisternino S; Auvity S; Truillet C
    Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293329
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of Novel RAS Signaling Therapeutic Vulnerabilities in Diffuse Intrinsic Pontine Gliomas.
    Koncar RF; Dey BR; Stanton AJ; Agrawal N; Wassell ML; McCarl LH; Locke AL; Sanders L; Morozova-Vaske O; Myers MI; Hamilton RL; Carcaboso AM; Kohanbash G; Hu B; Amankulor NM; Felker J; Kambhampati M; Nazarian J; Becher OJ; James CD; Hashizume R; Broniscer A; Pollack IF; Agnihotri S
    Cancer Res; 2019 Aug; 79(16):4026-4041. PubMed ID: 31201162
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The intersect of neurosurgery with diffuse intrinsic pontine glioma.
    Kuzan-Fischer CM; Souweidane MM
    J Neurosurg Pediatr; 2019 Dec; 24(6):611-621. PubMed ID: 31786541
    [TBL] [Abstract][Full Text] [Related]  

  • 34. DIPG-like MYB-altered diffuse astrocytoma with durable response to intensive chemotherapy.
    Trkova K; Sumerauer D; Krskova L; Vicha A; Koblizek M; Votava T; Priban V; Zapotocky M
    Childs Nerv Syst; 2023 Sep; 39(9):2509-2513. PubMed ID: 37165121
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Retrospective analysis on the consistency of MRI features with histological and molecular markers in diffuse intrinsic pontine glioma (DIPG).
    Giagnacovo M; Antonelli M; Biassoni V; Schiavello E; Warmuth-Metz M; Buttarelli FR; Modena P; Massimino M
    Childs Nerv Syst; 2020 Apr; 36(4):697-704. PubMed ID: 31848724
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Microtubule-Targeting Combined with HDAC Inhibition Is a Novel Therapeutic Strategy for Diffuse Intrinsic Pontine Gliomas.
    Ehteda A; Khan A; Rajakumar G; Vanniasinghe AS; Gopalakrishnan A; Liu J; Tsoli M; Ziegler DS
    Mol Cancer Ther; 2023 Dec; 22(12):1413-1421. PubMed ID: 37683275
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Children are not just little adults: recent advances in understanding of diffuse intrinsic pontine glioma biology.
    Schroeder KM; Hoeman CM; Becher OJ
    Pediatr Res; 2014 Jan; 75(1-2):205-9. PubMed ID: 24192697
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Noncoding RNAs as potential biomarkers for DIPG diagnosis and prognosis: XIST and XIST-210 involvement.
    Velázquez-Flores MÁ; Rodríguez-Corona JM; López-Aguilar JE; Siordia-Reyes G; Ramírez-Reyes G; Sánchez-Rodríguez G; Ruiz Esparza-Garrido R
    Clin Transl Oncol; 2021 Mar; 23(3):501-513. PubMed ID: 32661825
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting Mutant PPM1D Sensitizes Diffuse Intrinsic Pontine Glioma Cells to the PARP Inhibitor Olaparib.
    Wang Z; Xu C; Diplas BH; Moure CJ; Chen CJ; Chen LH; Du C; Zhu H; Greer PK; Zhang L; He Y; Waitkus MS; Yan H
    Mol Cancer Res; 2020 Jul; 18(7):968-980. PubMed ID: 32229503
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Integrated Metabolic and Epigenomic Reprograming by H3K27M Mutations in Diffuse Intrinsic Pontine Gliomas.
    Chung C; Sweha SR; Pratt D; Tamrazi B; Panwalkar P; Banda A; Bayliss J; Hawes D; Yang F; Lee HJ; Shan M; Cieslik M; Qin T; Werner CK; Wahl DR; Lyssiotis CA; Bian Z; Shotwell JB; Yadav VN; Koschmann C; Chinnaiyan AM; Blüml S; Judkins AR; Venneti S
    Cancer Cell; 2020 Sep; 38(3):334-349.e9. PubMed ID: 32795401
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.